Gamida Cell Announces 2019 Goals and Provides Company Update

San Francisco, CA, January 07, 2019 --(PRWirePro.com)-- Gamida Cell Ltd. (Nasdaq:GMDA), a leading cellular and immune therapeutics company, reported expected milestones for 2019, which highlight the company's progress advancing its clinical development candidates: NiCord®, an investigational universal bone marrow donor source in late-stage development for patients with hematologic malignancies (blood cancers), and NAM-NK, an investigational, cell-based cancer immunotherapy in development in patients with non-Hodgkin lymphoma and multiple myeloma. VIEW FULL PRESS RELEASE

Comments